SEATTLE — Among bariatric surgery patients treated with denosumab to counter bone loss, follow-up treatment with zoledronic acid prevented the rebound effect on markers of bone turnover that is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback